# Statines voor primaire cardiovasculaire preventie: USPSTF-aanbeveling

*geplaatst 2016-11-15 · Cholesterol · JAMA · doi 10.1001/jama.2016.15450 · https://hartvaat.nl/2016/11/15/statines-voor-primaire-cardiovasculaire-preventie-uspstf-aanbeveling/*

USPSTF-aanbeveling voor statinegebruik bij de primaire preventie van cardiovasculaire ziekte bij volwassenen. Definieert drempelwaarden en indicaties voor statine-initiatie.

## English: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

The USPSTF recommendation endorsed statin use for primary cardiovascular prevention in adults aged 40–75 with at least one CVD risk factor and a 10-year risk of 10% or greater. The guideline defined evidence-based thresholds for initiating statin therapy in adults without established cardiovascular disease.

## Abstract (original, from the publication)

IMPORTANCE: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. OBJECTIVE: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. EVIDENCE REVIEW: The USPSTF reviewed the evidence on the benefits and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. CONCLUSIONS AND RECOMMENDATIONS: The USPSTF recommends initiating use of low- to moderate-dose statins in adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and a calculated 10-year CVD event risk of 10% or greater (B recommendation). The USPSTF recommends that clinicians selectively offer low- to moderate-dose statins to adults aged 40 to 75 years without a history of CVD who have 1 or more CVD risk factors and a calculated 10-year CVD event risk of 7.5% to 10% (C recommendation). The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use in adults 76 years and older (I statement).

Auteurs: Kirsten Bibbins-Domingo, David C Grossman, Susan J Curry, Karina W Davidson, John W Epling, Francisco A R García, Matthew W Gillman, Alex R Kemper, Alex H Krist, Ann E Kurth, C Seth Landefeld, Michael L LeFevre, Carol M Mangione, William R Phillips, Douglas K Owens, Maureen G Phipps, Michael P Pignone

---
Bron: JAMA, https://doi.org/10.1001/jama.2016.15450. Bijgewerkt 2026-07-03T13:25:44Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.